aztreonam (Cayston®)

EOCCO POLICY

Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO008

Description

Aztreonam (Cayston) inhibits bacterial cell wall synthesis by binding to one or more penicillin-binding proteins (PBPs), which inhibits the final transpeptidation step of peptidoglycan synthesis. Bacteria lyse due to ongoing activity of cell wall autolytic enzymes while cell wall assembly is arrested.

Length of Authorization

- Initial: Six months
- Renewal: Twelve months

Quantity limits

Product Name	Dosage Form	Indication	Quantity Limit	DDID
aztreonam (Cayston)	75 mg/vial inhalation powder	Cystic Fibrosis (CF)	6,300 mg (84 vials)/28 days*	147190

* total of 7 fills in one year

Initial Evaluation

I. Aztreonam (Cayston) may be considered medically necessary when the following criteria are met:
   A. Prescribed by or in consultation with a pulmonologist; **AND**
   B. Member is 7 years of age and older; **AND**
   C. A diagnosis of **cystic fibrosis with Pseudomonas aeruginosa** when the following are met:
      1. Member has a FEV_1 of 25% to 75% predicted; **AND**
      2. Is not allergic to beta-lactam antibiotics (e.g. penicillins, cephalosporins, and/or carbapenems)

Renewal Evaluation

I. Member has received a previous prior authorization approval for this agent; **AND**
II. Member has exhibited improvement or stability of disease symptoms

Supporting Evidence

I. Aztreonam (Cayston) was studied in a randomized, double-blind, placebo-controlled, multicenter trial that enrolled 164 patients who were seven years of age or older with cystic fibrosis (CF) and pseudomonas aeruginosa (P. aeruginosa) colonization for a period of 28 days.

The treatment difference at Day 28 between the patients in the aztreonam (Cayston) arm and placebo arm were 10% (95% CI: 6%, 14%), the FEV_1 was statistically significant favoring the aztreonam (Cayston) arm.

References

1. Cayston [Prescribing Information]. Foster City, CA: Gilead Sciences, Inc. September 2012.

Policy Implementation/Update:

Date Created	July 2011
Date Effective	July 2011
Last Updated	February 2019, December 2011
Last Reviewed	February 2019

Action and Summary of Changes	Date
Criteria update: The FEV_1 requirements were added to initial criteria as that was part of the inclusion criteria. Additionally, renewal criteria and supporting evidence sections were added.	10/2019
Criteria update: quantity limit has been updated to reflect the clinical use of Cayston.	2/2019